WallStSmart

Spectral AI Inc. (MDAI)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 287829% more annual revenue ($56.58B vs $19.65M). NVS leads profitability with a 23.9% profit margin vs -38.5%. NVS earns a higher WallStSmart Score of 51/100 (C-).

MDAI

Avoid

16

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 6.7Quality: 5.0

NVS

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 9.0Value: 4.0Quality: 5.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDAIUndervalued (+50.5%)

Margin of Safety

+50.5%

Fair Value

$3.11

Current Price

$1.94

$1.17 discount

UndervaluedFair: $3.11Overvalued
NVSSignificantly Overvalued (-52.5%)

Margin of Safety

-52.5%

Fair Value

$109.60

Current Price

$147.85

$38.25 premium

UndervaluedFair: $109.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDAI0 strengths · Avg: 0/10

No standout strengths identified

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$282.11B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
34.9%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

Areas to Watch

MDAI4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$61.74M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-2308.0%2/10

ROE of -2308.0% — below average capital efficiency

Revenue GrowthGrowth
-46.3%2/10

Revenue declined 46.3%

NVS4 concerns · Avg: 3.0/10
PEG RatioValuation
2.484/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth
-9.3%2/10

Earnings declined 9.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : MDAI

MDAI has a balanced fundamental profile.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bear Case : MDAI

The primary concerns for MDAI are EPS Growth, Market Cap, Return on Equity.

Bear Case : NVS

The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.

Key Dynamics to Monitor

MDAI profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.

MDAI carries more volatility with a beta of 0.91 — expect wider price swings.

NVS is growing revenue faster at -0.7% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (51/100 vs 16/100), backed by strong 23.9% margins. MDAI offers better value entry with a 50.5% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Spectral AI Inc.

HEALTHCARE · MEDICAL DEVICES · USA

Spectral MD Holdings, Ltd., a predictive analytics company, develops AI algorithms and optical technology in wound care treatment. The company is headquartered in Dallas, Texas.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?